Key result
ApHCM linked to annual cardiac death rates up to ~4%, approaching classic HCM risk.
Why the study?
No authoritative ApHCM-specific recommendations to guide diagnosis, family screening, and patient risk stratification currently exist despite its distinctive clinical and genetic features compared with classic HCM.
null
Effect estimate: null (95% CI null)
Absolute Event Rate: 0.5% vs 4%
p-value: p=null
ApHCM is a distinct morphological subtype of hypertrophic cardiomyopathy with unique genetic, clinical, and prognostic features that currently lacks specific management guidelines.
No takes yet. Share an insight, caveat, or question.
ApHCM mortality approaches classic HCM rates; challenges benign perception and leaves open dedicated guidelines.
Hughes et al. (2020) conducted a null in apical hypertrophic cardiomyopathy. null vs. null was evaluated on cardiac death rates (null, 95% CI null, p=null). ApHCM was associated with annual cardiac death rates ranging from 0.5% to 4%, approaching those for classic HCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: